NKTR-214

Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Endpoints
Wed, 02/17/21 - 11:00 am
Nektar Therapeutics
Bristol-Myers Squibb
NKTR-214
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Mon, 11/11/19 - 10:53 am
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
This Bristol-Partnered Biotech Stock Just Fumbled On A Cancer Study
Investors Business Daily
Thu, 09/26/19 - 07:39 pm
Bristol-Myers Squibb
Nektar Therapeutics
breast cancer
clinical trials
NKTR-214
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
BioCentury
Wed, 06/5/19 - 12:12 am
ASCO 2019
NKTR-214
Nektar Therapeutics
metastatic melanoma
Complete response rate in Nektar melanoma trial hits 34%
Fierce Biotech
Sun, 06/2/19 - 01:12 pm
Nektar
NKTR-214
Opdivo
ASCO 2019
melanoma
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Yahoo/Reuters
Sat, 02/16/19 - 03:53 pm
Nektar
Bristol-Myers Squibb
bladder cancer
NKTR-214
Opdivo
Bladder cancer readout sees Nektar shares hit
Fierce Biotech
Tue, 02/12/19 - 11:36 am
Nektar Therapeutics
bladder cancer
NKTR-214
Opdivo
Bristol-Myers Squibb
Here's Why Nektar Therapeutics Surged Today
Motley Fool
Tue, 01/8/19 - 07:12 pm
Nektar Therapeutics
JPMHC 2019
NKTR-214
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
Sun, 01/6/19 - 02:09 pm
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Tue, 11/6/18 - 11:35 am
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst
Fierce Biotech
Mon, 10/1/18 - 09:42 am
Nektar Therapeutics
NKTR-214
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Sun, 06/3/18 - 10:00 am
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
Thu, 05/17/18 - 10:44 pm
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
CP Wire
Wed, 04/11/18 - 09:36 am
Nektar Therapeutics
NKTR-214
NKTR-262
cancer
solid tumors
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
Wed, 04/11/18 - 09:18 am
Nektar
NKTR-214
NKTR-262
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
Motley Fool
Fri, 04/6/18 - 07:41 pm
Nektar Therapeutics
Incyte
Merck
NKTR-214
Bristol-Myers Squibb
Why Alkermes Sunk Today
Motley Fool
Thu, 02/22/18 - 11:17 pm
Alkermes
ALKS-4230
Nektar
NKTR-214
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Forbes
Wed, 02/14/18 - 11:51 am
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-214
cancer
3 Promising Cancer Immunotherapies to Watch in 2018
Yahoo/Motley Fool
Fri, 12/22/17 - 09:46 am
cancer
immuno-oncology
Incyte
epacadostat
Bristol-Myers Squibb
relatlimab
Nektar
NKTR-214
Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results
NASDAQ.com
Mon, 11/13/17 - 10:54 am
Nektar
NKTR-214
Opdivdo
Bristol-Myers Squibb

Pages